Meeting
2020 ASCO Virtual Scientific Program
Patient preferences and expectations of systemic therapy in renal cell carcinoma.
Authors
Dena Battle
KCCure, Alexandria, VA
Dena Battle , Cristiane Decat Bergerot , Pavlos Msaouel , Eric Jonasch , Tian Zhang , Daniel J. George , Michael D. Staehler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5083)
DOI
10.1200/JCO.2020.38.15_suppl.5083
Abstract #
5083
Poster Bd #
152
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
First Author: Bradley Alexander McGregor
Poster
2023 ASCO Genitourinary Cancers Symposium
Cross-sectional study of patients' (pts) and physicians' needs and the financial toxicity of systemic treatment for metastatic renal cell carcinoma (mRCC) in Japan.
First Author: Takahiro Osawa
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang
Poster
2019 Genitourinary Cancers Symposium
Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer.
First Author: Yuanyuan Zhang